These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21612875)

  • 1. Minimal residual disease in solid neoplasia: New frontier or red-herring?
    Mordant P; Loriot Y; Lahon B; Castier Y; Lesèche G; Soria JC; Massard C; Deutsch E
    Cancer Treat Rev; 2012 Apr; 38(2):101-10. PubMed ID: 21612875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of minimal residual cancer cell research].
    Iinuma H; Watanabe T
    Nihon Geka Gakkai Zasshi; 2012 Mar; 113(2):177-84. PubMed ID: 22582577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequences.
    Köstler WJ; Brodowicz T; Hejna M; Wiltschke C; Zielinski CC
    Cancer Detect Prev; 2000; 24(4):376-403. PubMed ID: 11059569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Isolated tumor cells and micrometastasis--clinical behavior and therapeutic implications].
    Toi M; Matsumoto G
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1315-36. PubMed ID: 10969586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells.
    Ghossein RA; Rosai J
    Cancer; 1996 Jul; 78(1):10-6. PubMed ID: 8646704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor dormancy and identification of therapeutic targets].
    Li CF; Cao S; Meng SD
    Ai Zheng; 2009 May; 28(5):555-8. PubMed ID: 19624889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
    Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
    Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?
    Lang JE; Hall CS; Singh B; Lucci A
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1463-72. PubMed ID: 17944570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated and circulating tumor cells: Role in effective cancer management.
    Lin H; Balic M; Zheng S; Datar R; Cote RJ
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):1-11. PubMed ID: 20570170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer.
    Gavioli M; Luppi G; Losi L; Bertolini F; Santantonio M; Falchi AM; D'Amico R; Conte PF; Natalini G
    Dis Colon Rectum; 2005 Oct; 48(10):1851-7. PubMed ID: 16132481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterisation of minimal residual disease in solid tumors.
    Pantel K; Otte M
    Acta Med Austriaca Suppl; 2000; 52():8-12. PubMed ID: 11261279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients.
    Austrup F; Uciechowski P; Eder C; Böckmann B; Suchy B; Driesel G; Jäckel S; Kusiak I; Grill HJ; Giesing M
    Br J Cancer; 2000 Dec; 83(12):1664-73. PubMed ID: 11104564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease and circulating tumor cells in breast cancer: open questions for research.
    Ignatiadis M; Sotiriou C; Pantel K
    Recent Results Cancer Res; 2012; 195():3-9. PubMed ID: 22527490
    [No Abstract]   [Full Text] [Related]  

  • 14. Micrometastatic disease in breast cancer: clinical implications.
    Ignatiadis M; Georgoulias V; Mavroudis D
    Eur J Cancer; 2008 Dec; 44(18):2726-36. PubMed ID: 19056036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Minimal residual disease in solid cancer. Prognostic value and therapeutic consequences].
    Allgayer H; Heiss MM
    Fortschr Med Orig; 2001; 119(1):1-4. PubMed ID: 11935652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and clinical significance of occult tumour cells in colorectal cancer.
    Tsavellas G; Patel H; Allen-Mersh TG
    Br J Surg; 2001 Oct; 88(10):1307-20. PubMed ID: 11578283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
    Feller N; Jansen-van der Weide MC; van der Pol MA; Westra GA; Ossenkoppele GJ; Schuurhuis GJ
    Exp Hematol; 2005 Jan; 33(1):120-30. PubMed ID: 15661405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and significance of minimal residual disease in patients with colorectal carcinoma].
    von Knebel Doeberitz M; Koch M; Weitz J; Herfarth C
    Zentralbl Chir; 2000; 125 Suppl 1():15-9. PubMed ID: 10929641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Minimal residual disease in gastrointestinal tumors: tumor detection in bone marrow, blood and lymph nodes].
    Rosenberg R; Nekarda H; Thorban S; Siewert JR
    Acta Med Austriaca Suppl; 2002; 59():42-53. PubMed ID: 12506760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis.
    Hermanek P; Hutter RV; Sobin LH; Wittekind C
    Cancer; 1999 Dec; 86(12):2668-73. PubMed ID: 10594862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.